

# VA Committee

**Friday, April 5, 2024 | 3:00 PM – 5:00 PM PT**

**Room: Beckler / 302**

## **A. Introductions and Opening Comments**

*- Stephen Bartlett, RPh, MSPH*

## **B. Studies for VA Consideration from the VA Oncology Consortium**

**FORTE (NRG-NC005) – Five to Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps**

*- Dr. Lisa A. Kachnic, SWOG Study Champion, Columbia Univ Irving Med Ctr*

## **C. Treatment Perspectives**

**The Effectiveness of MRD in the Treatment of Myeloma**

*- Dr. Thomas R. Chauncey, MAVERIC/VA Puget Sound Health Care System*

*- Dr. J. Christine Ye, MD Anderson Cancer Center*

## **D. Studies for VA Consideration from SWOG**

**1. S2302, “Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer)”**

*- Study Updates:*

*- Dr. Cheryl M. Czerlanis, Loyola Univ, Hines VA Medical Center*

*VA Liaison on Lung Committee*

**2. S2414, “INcorporating pathologic reSponse in patlents with early staGe lung cancer to optimize immunoTherapy in the adjuvanT setting (INSIGHT)”**

*- Dr. Chao Hui Huang, VAMC Kansas City*

*VA Liaison on Lung Committee*

# VA Committee, continued

## **E. VA Disease Committee Liaisons Updates and Needs**

### **1. New Disease VA Committee Members:**

<i>Cancer Survivorship</i>	<i>Neha Patel, MD – VAMC Long Beach</i>
<i>Gastrointestinal</i>	<i>Rangaswamy Govindarajan, MD – Central Arkansas VA</i>
<i>Symptom Control &amp; Quality of Life</i>	<i>Jacqueline Gesek, BSN, RN – White River Junction VA</i>

### **2. Open Committee Needs:**

<i>Cancer Care Delivery</i>	<i>Melanoma</i>
<i>Early Therapeutics</i>	<i>Palliative &amp; End of Life</i>
<i>Immunotherapeutics</i>	<i>Prevention &amp; Epidemiology</i>

**How to Apply – [vamember@swog.org](mailto:vamember@swog.org)**

## **F. Current VA Stats**

*Accrual/sites – SWOG Report*

## **G. VA Program Development Team**

*Mission goals in place; definable action items and strategies well under way. Several accomplishments thus far, to include:*

- *Defined VA Liaison responsibilities and expectations*
- *VA Liaison meet/greet April Group Meeting*

## **H. Other**

- 1. NRG collaboration*
- 2. VA GUPOP (GU Precision Oncology Program)*

## **I. Future Meetings**

- 1. AVAHO Annual Meeting, Atlanta, September 20 – 22, 2024*
- 2. SWOG Fall Group Meeting, Chicago, October 16 - 29, 2024*